-
Cell Journal: Meal Replacement for Cancer Treatment?
Time of Update: 2021-11-12
In particular, the three drugs targeting PI3K/AKT and mTOR have a strong effect on the progression-free survival of mice fed a standard diet, but the addition of the FMD cycle resulted in significant anti-tumor activity of the triple combination of PI3K/AKT and mTOR pathway inhibitors Enhanced .
-
N Engl J Med 2021: The overall survival benefit of tebentafusp in patients with metastatic uveal melanoma
Time of Update: 2021-11-12
In a single-group phase 2 study involving 127 previously treated patients with metastatic uveal melanoma, tebentafusp monotherapy showed a more promising overall survival than historical controls .
-
Front Oncol: Palbociclib combined with letrozole in the first-line treatment of HR+ /HER2- predictors of primary drug resistance in metastatic breast cancer (MBC)
Time of Update: 2021-11-12
Recently, scholars from South Korea have carried out related studies to assess which clinical parameters can predict the primary drug resistance of palbociclib combined with letrozole as the first-line treatment of HR+ /HER2-MBC patients .
-
Ann Oncol: The prognosis of patients with hormone receptor (HR) low-positive breast cancer: Based on the results of a 15-year population cohort study
Time of Update: 2021-11-12
In the HER2-positive subgroup (n=5194), the 10-year OS of patients with negative HR, low positive HR, and strong positive HR were 72%, 73%, and 74%, respectively .
-
European Radiology: Differential diagnosis of palatine tonsil squamous cell carcinoma and non-Hodgkin's lymphoma by CT radiomic nomogram
Time of Update: 2021-11-12
Recently, published in the E uropean a journal Radiology research to develop and validate a based on enhanced CT (CECT) images including radiology group characteristics and clinical factors of radiation genomics nomogram previous figure for SCC and palatine tonsil surgery NHL Differential diagnosis , provides radiological support for the patient treatment plan .
-
Eur Urol: What is the quality of life of patients undergoing radical cystectomy?
Time of Update: 2021-11-12
Researchers from the United States published an article in "Eur Urol" and they evaluated HRQOL outcomes in a large RC cohort.
Researchers from the United States published an article in "Eur Urol" and they evaluated HRQOL in a large RC cohort.
-
Journal of Urology: Shanghai Jiaotong University's Chen Haige team's major achievement: non-invasive and accurate diagnosis of bladder cancer with just a few milliliters of urine
Time of Update: 2021-11-12
Recently, Professor Chen Haige's team from the Department of Urology, Renji Hospital, Shanghai Jiaotong University School of Medicine, published an important research result titled: Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer in the Journal of Urology as a cover paper .
-
JACC: Cancer treatment milestone-pay attention to cardiopulmonary adverse events of universal CAR-T therapy!
Time of Update: 2021-11-12
Thrombosis arrhythmiaIn summary, the study found that CAR-T is associated with cardiopulmonary adverse events including tachycardia, cardiomyopathy, pericardial and pleural diseases, and VTEs .
In summary, the study found that CAR-T is associated with cardiopulmonary adverse events including tachycardia, cardiomyopathy, pericardial and pleural diseases, and VTEs .
-
Br J Cancer: Analysis of the efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
Time of Update: 2021-11-12
This study aims to reveal the anti-tumor efficacy of CDK4/6 inhibitors in preclinical models of MPM and to study their potential in the treatment of MPM .
-
Cancer Commun: Paclitaxel Liposome + Cisplatin vs. Gemcitabine + Cisplatin First-line Therapeutic Efficacy of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung: A Multicenter Randomized Controlled Study
Time of Update: 2021-11-12
Studies have shown that for patients with locally advanced or metastatic LSCC, the PFS, OS, ORR and DCR of the LP regimen are similar to those of the GP regimen, but have more favorable toxicity .
-
Nature Sub-Journal: Calorie restriction wins!
Time of Update: 2021-11-12
Using a mouse breast cancer model, we compared the effectiveness of daily CR with FMD or isocaloric standard laboratory food's periodic caloric cycle on primary tumor growth and metastatic burden .
-
Liver Cancer: The impact of immune-related adverse events (irAEs) on the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced hepatocellular carcinoma
Time of Update: 2021-11-12
Compared with patients without irAEs, patients with any grade of irAEs have a longer median progression-free survival (PFS) (5.
Compared with patients without irAEs, patients with any grade of irAEs have a longer median progression-free survival (PFS) (5.
-
Front Oncol: Weekly PCC regimen (paclitaxel + carboplatin + cetuximab) can be used for patients who are not suitable for EXTREME regimen to treat recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC)
Time of Update: 2021-11-12
OS OS OSIn summary, studies have shown that for R/M-HNSCC that is not suitable for EXTREME treatment, the weekly PCC regimen is an optional regimen .
In summary, studies have shown that for R/M-HNSCC that is not suitable for EXTREME treatment, the weekly PCC regimen is an optional regimen .
-
FDA approves Scemblix (asciminib) for the treatment of chronic myeloid leukemia
Time of Update: 2021-11-12
Based on the primary molecular response (MMR) rate at 24 weeks, the FDA has accelerated the approval of Scemblix for the Philadelphia chromosome-positive CML chronic phase (Ph+ CML-CP) that has been treated with two or more tyrosine kinase inhibitors (TKI).
-
Front Oncol: Effectiveness and safety of Anlotinib in the treatment of Chinese patients with recurrent or metastatic cervical cancer
Time of Update: 2021-11-12
In summary, research shows that this is the first study to evaluate the effectiveness and safety of Anlotinib in patients with recurrent or metastatic cervical cancer in China .
-
Eur Urol: In ccRCC patients, how effective is PARP1 in predicting the response to PD-L1 blockade?
Time of Update: 2021-11-12
So as to improve the curative effect, effective biomarkers can be found to predict the response of ICI, thereby improving the curative effectCurrently, Immune Checkpoint Inhibitors (ICI) have become a key drug for the treatment of clear cell renal cell carcinoma (ccRCC), but their efficacy is limited and responders cannot be identified .
-
Lancet Oncol: Radiotherapy can delay the systemic treatment time of oligometastatic renal cell carcinoma
Time of Update: 2021-11-12
4-not reached), one-year progression-free survival rate was 64%Survival without system treatmentIn summary, sequential radiotherapy may help delay the start of systemic treatment and may allow patients with specific oligometastatic renal cell carcinoma to continue to interrupt systemic treatment .
-
J Urol: Which type of muscular invasive bladder cancer patients benefit the most from platinum-based neoadjuvant chemotherapy?
Time of Update: 2021-11-12
Factors affecting the use of NAC involve the patient’s comorbidities and potential chemotherapy Related toxicity, risk of disease progression in unresponsive patients, delay in local treatment, and choice of chemotherapy regimensThere is evidence that molecular differences between tumors may affect the response to treatment .
-
Science Sub-Journal: Providing a "wake-up service" for the immune system may effectively eliminate tumors in the body!
Time of Update: 2021-11-12
In this study, the researchers etoposide ( Etoposide treatment) tumor cells in vitro, to obtain DNA of tumor cell damage, and it is then injected into a cancer tumor in vivo in mice, systemic checkpoint inhibitor Used in combination .
-
J Clin Oncol: The chief culprit of brain cognitive decline after breast cancer chemotherapy
Time of Update: 2021-11-12
Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer.
Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer.
